The Journal of antimicrobial chemotherapy · 2003
The bacteriocin piscicolin 126 retains antilisterial activity in vivo.
Сравнительное исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ingham Aaron, Ford Mark, Moore Robert J, Tizard Mark
Аннотация
OBJECTIVE: We have conducted a series of experiments to show that the bacteriocin piscicolin 126 (P126) retains antilisterial activity after injection into a mouse.
METHODS: Groups of mice were challenged intravenously with Listeria monocytogenes and treated with purified P126 at varying times before and after challenge to determine whether administration of this peptide reduced numbers of colonizing L. monocytogenes and the symptoms of listeriosis.
RESULTS: The bacteriocin P126 retained antilisterial activity after injection into the mouse. During the early time-points of listerial infection, the purified P126 was found to significantly reduce the listerial load in the liver and spleen and, further, that this reduction translated to reduced clinical signs of disease.
CONCLUSIONS: This is the first report of a Class IIA bacteriocin displaying in vivo antimicrobial activity. Such a result provides preliminary evidence that this class of molecules may be useful in controlling systemic bacterial infections.
METHODS: Groups of mice were challenged intravenously with Listeria monocytogenes and treated with purified P126 at varying times before and after challenge to determine whether administration of this peptide reduced numbers of colonizing L. monocytogenes and the symptoms of listeriosis.
RESULTS: The bacteriocin P126 retained antilisterial activity after injection into the mouse. During the early time-points of listerial infection, the purified P126 was found to significantly reduce the listerial load in the liver and spleen and, further, that this reduction translated to reduced clinical signs of disease.
CONCLUSIONS: This is the first report of a Class IIA bacteriocin displaying in vivo antimicrobial activity. Such a result provides preliminary evidence that this class of molecules may be useful in controlling systemic bacterial infections.